Buscar
Spero Therapeutics Inc
SPROAñadir a la lista de seguimiento
2.200USD
-0.020-0.90%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
127.38MCap. mercado
7.92P/E TTM
Más Datos de Spero Therapeutics Inc Compañía
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Información de Spero Therapeutics Inc
Símbolo de cotizaciónSPRO
Nombre de la empresaSpero Therapeutics Inc
Fecha de salida a bolsaNov 02, 2017
Director ejecutivoRajavelu (Esther)
Número de empleados32
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 02
Dirección675 Massachusetts Ave Ste 14
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02139-3309
Teléfono18572421600
Sitio Webhttps://sperotherapeutics.com/
Símbolo de cotizaciónSPRO
Fecha de salida a bolsaNov 02, 2017
Director ejecutivoRajavelu (Esther)
Ejecutivos de Spero Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.80%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
-27.99%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
55.00K
-36.36%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
-36.36%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
55.00K
-36.36%
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. John C. Pottage, Jr., M.D.
Dr. John C. Pottage, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.80%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
-27.99%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
55.00K
-36.36%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
-36.36%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Spero Therapeutics Inc?
Los cinco principales accionistas de Spero Therapeutics Inc son: Dr. Ankit Mahadevia, M.D.
¿Cuántas instituciones poseen acciones de Spero Therapeutics Inc (SPRO)?
A fecha de 2026Q1, 117 instituciones poseen acciones de Spero Therapeutics Inc, con un valor de mercado combinado de aproximadamente 11.81M, lo que representa el 20.40% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -1291189.00.
¿Cuál es la mayor fuente de ganancias de Spero Therapeutics Inc?
El 2026Q1, el segmento empresarial Collaboration Revenue Related Party generó la ganancia más alta para Spero Therapeutics Inc, ascendiendo a 47.03M y representando el 70.41% de la ganancia total.